Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSenseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc. Common Stock

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
12.855 USD 3.06 ( 31.17%)
Last update at 2026-11-10T14:54:00Z
VOLUME
1627856
Market Cap
469.52M

Momentum Score

…

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11.91
Low
13.98
High
52 Week Price Range
4.79
Low
11.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Senseonics Holdings develops and commercialized the Eversense implantable continuous glucose monitoring (CGM) system for people with diabetes, offering a differentiated approach versus transcutaneous sensors. Major long-term growth drivers include broader CGM adoption, expanded reimbursement and distribution, and product iterations that could support higher patient retention and recurring revenue; these factors may benefit market penetration and revenue growth. Investors may find the company attractive for its unique clinical positioning within the diabetes technology market.

Principal investment risks include intense competition from larger CGM manufacturers, reimbursement and payer acceptance uncertainty, execution and regulatory risks tied to commercialization, and a history of limited scale and profitability.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.80
Dividend Yield
-
Revenue TTM
48.55M
Revenue Per Share
1.00
Gross Profit TTM
26.64M
Debt / Equity
0.68
ROE
-118.24%
Net Debt
0.82M
ROCE
-62.95%
Diluted EPS TTM
-2.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -69.11M -78.62M -60.39M 142.12M -302.48M
Net income -69.11M -78.62M -60.39M 142.12M -317.78M
Selling general administrative 52.51M 34.23M 30.45M 31.63M 21.54M
Selling and marketing expenses - - - - 7.62M
Gross profit 15.76M 0.53M 3.09M 2.73M -0.81M
Reconciled depreciation 1.51M 1.48M 0.88M 0.98M 1.24M
Ebit -64.16M -70.18M -49.28M -68.63M -57.18M
Ebitda -62.65M -68.70M -48.01M -66.91M -57.11M
Depreciation and amortization 1.51M 1.48M 1.28M 1.72M 0.07M
Non operating income net other - - - 228.98M -228.78M
Operating income -68.34M -74.84M -75.60M -68.63M -57.18M
Other operating expenses 103.59M 97.31M 97.99M 85.02M 70.86M
Interest expense 4.95M 8.44M 11.11M 18.70M 16.72M
Interest income 4.20M 4.50M 4.83M 1.82M 0.24M
Net interest income -0.75M -3.94M -9.46M -16.88M -16.48M
Income tax expense - - 1.11M 18.70M 15.31M
Total revenue 35.26M 22.47M 22.39M 16.39M 13.68M
Total operating expenses 84.10M 75.38M 78.69M 71.35M 56.37M
Cost of revenue 19.49M 21.94M 19.30M 13.66M 14.49M
Total other income expense net -0.78M -3.77M 15.21M 210.75M -245.29M
Net income from continuing ops -69.11M -78.62M -31.64M 141.65M -302.69M
Net income applicable to common shares - - - 142.12M -302.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 126.27M 100.44M 138.22M 177.67M 198.93M
Intangible assets 0.80M 0.48M - - -
Other current assets 4.37M 4.34M 5.20M 7.43M 0.03M
Total liab 65.22M 116.99M 102.42M 180.25M 384.46M
Total stockholder equity 61.05M -16.55M 35.80M -2.58M -185.53M
Deferred long term liab - - - 52.05M 236.29M
Other current liab 19.79M 15.08M 12.32M 15.47M 0.00M
Common stock 0.04M 0.59M 0.53M 0.48M 0.45M
Capital stock 0.04M 0.59M 0.53M 0.48M 0.45M
Retained earnings -1016.99M -947.87M -869.26M -808.87M -950.99M
Other liab - - - 52.05M 306.27M
Other assets - - 0.00M 0.08M 198.93M
Cash 40.55M 74.60M 75.71M 35.79M 33.46M
Total current liabilities 24.35M 38.85M 17.26M 31.47M 18.39M
Current deferred revenue - - - - 14.26M
Net debt 0.82M -13.54M -27.93M 38.86M 29.84M
Short term debt 0.50M 20.57M 0.37M 15.58M 2.93M
Short long term debt - 20.14M - 15.58M 2.93M
Short long term debt total 41.37M 61.05M 47.78M 74.65M 63.30M
Other stockholder equity 1077.92M 930.72M 904.53M 768.83M 765.22M
Property plant equipment - - - 1.11M 1.31M
Total current assets 117.53M 91.44M 130.03M 161.20M 144.41M
Long term investments - - 0.00M 12.25M 52.12M
Net tangible assets - - - 35.08M -185.53M
Short term investments 53.80M 0.00M 33.75M 108.22M 96.44M
Net receivables 12.43M 8.08M 6.60M 2.45M 1.97M
Long term debt 35.59M 34.70M 41.20M 56.38M 59.80M
Inventory 6.70M 4.42M 8.78M 7.31M 6.32M
Accounts payable 4.06M 3.21M 4.57M 0.42M 1.20M
Accumulated other comprehensive income 0.07M - -0.01M -0.68M -0.21M
Common stock total equity - - - 0.48M 0.45M
Retained earnings total equity - - - -808.87M -950.99M
Non currrent assets other 3.74M 4.93M 7.01M 3.11M 1.32M
Non current assets total 8.74M 9.00M 8.19M 16.47M 54.52M
Capital lease obligations 5.79M 5.79M 6.58M 2.69M 0.90M
Long term debt total - - - 56.38M 59.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -52.31M 32.84M 60.87M 27.19M -148.54M
Change to liabilities - - - 0.58M 1.13M
Total cashflows from investing activities -53.42M 32.84M 89.71M 26.88M -148.75M
Net borrowings -20.40M 9.95M 1.25M -2.93M -2.84M
Total cash from financing activities 78.19M 26.83M 20.37M 41.76M 220.08M
Change to operating activities - - - -0.22M -0.92M
Net income -69.11M -78.62M -60.39M 142.12M -302.47M
Change in cash -34.36M -0.80M 39.92M 2.33M 15.26M
Begin period cash flow 74.91M 75.71M 35.79M 33.46M 18.20M
End period cash flow 40.55M 74.91M 75.71M 35.79M 33.46M
Total cash from operating activities -59.13M -60.47M -70.16M -66.31M -56.08M
Issuance of capital stock 100.59M 18.36M 19.11M 46.17M 22.78M
Depreciation 0.09M 1.48M 1.28M 0.98M 1.24M
Change to inventory -2.98M 0.70M -1.64M -0.99M -1.04M
Change to account receivables -6.76M -2.70M -2.19M -0.48M 1.01M
Sale purchase of stock - - -2.67M 46.17M 223.15M
Other cashflows from financing activities -2.15M -1.48M 11.74M 10.51M 22.56M
Change to netincome - - - 8.62M 9.56M
Capital expenditures 1.12M 2.24M 0.35M 0.31M 0.21M
Change receivables - - - -0.48M 1.01M
Cash flows other operating - - - -217.15M 234.50M
Cash and cash equivalents changes - - - 2.33M 15.26M
Change in working capital -3.28M 0.86M -3.97M -2.47M -1.50M
Stock based compensation 10.15M 9.22M 8.67M 8.62M 9.03M
Other non cash items 3.02M 6.59M -15.76M -215.56M 8.46M
Free cash flow -60.24M -62.70M -70.51M -66.62M -56.29M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SENS
Senseonics Holdings, Inc. Common Stock		 3.06
31.17%		 12.86 - 21.01 9.67 5.20 8.01 1.76
ABT
Abbott Laboratories		 -1.17
1.06%		 109.34 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -1.38
1.34%		 101.42 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -6.18
1.90%		 319.55 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -0.98
1.99%		 48.27 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

20451 Seneca Meadows Parkway, Germantown, MD, United States, 20876-7005

301 515 7260

https://www.senseonics.com

130

Name Title Year Born
Dr. Timothy T. Goodnow Pres, CEO & Director 1962
Dr. Mukul Jain Chief Operating Officer 1973
Dr. Francine Ratner Kaufman M.D. Chief Medical Officer & Director 1951
Mr. Frederick T. Sullivan CFO & Principal Accounting Officer 1981
Mr. Kenneth L. Horton Gen. Counsel & Corp. Devel. Advisor 1967
Dr. Timothy T. Goodnow Ph.D. President, CEO & Director 1962
Mr. Frederick T. Sullivan CPA CFO, Secretary & Treasurer 1982
Dr. Mukul Jain Ph.D. Chief Operating Officer 1973
Mr. Brian B. Hansen Chief Commercial Officer & Director 1968
Mr. Kenneth L. Horton J.D. General Counsel & Corporate Development Advisor 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

No data available
No data available

Equity Sectors*

  • Basic Materials

    -2.54%

  • Communication Services

    +0.09%

  • Consumer Cyclical

    -0.16%

  • Consumer Defensive

    -0.14%

  • Energy

    -1.11%

  • Financial Services

    +0.15%

  • Healthcare

    -0.77%

  • Industrials

    -0.93%

  • Real Estate

    -0.17%

  • Technology

    -0.09%

  • Utilities

    -0.67%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…